Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Osimertinib Shows Strength in NSCLC with Leptomeningeal Metastases

Key clinical point: Treatment with osimertinib leads to clinically meaningful responses in about half of patients with epidermal growth factor receptor T790M–positive non–small cell lung cancer who have asymptomatic leptomeningeal metastases.

Major finding: The overall response rate was 55%.

Study details: A subset analysis of patients with leptomeningeal metastasis from four AURA trials.

Disclosures: The study was funded by AstraZeneca. The investigators reported financial relationships with Novartis, Pfizer, Roche, and others.

Citation:

Ahn MJ et al. ELCC 2019, Abstract 105O.